Microdosing and PTSD: what the research says (and doesn't).
A summary of what the peer-reviewed literature actually shows about microdosing psychedelics for post-traumatic stress disorder.
If you landed here from a search, the question is probably some version of: can microdosing actually help with PTSD? This page is the clearest answer I can give based on what's currently in print. The short version: the clinical evidence for microdosing specifically — at any dose, for any condition — is still thin. The clinical evidence for full-dose psychedelic-assisted therapy in PTSD is stronger. The two are different practices with separate evidence bases.
No medical claims are made anywhere on this page. I'm a doctoral candidate, not a clinician. If you're in crisis, see the crisis resources before anything else.
What microdosing actually is
Microdosing is the practice of taking sub-perceptual doses of a psychedelic substance — typically lysergic acid diethylamide (LSD) or psilocybin — on a recurring schedule. "Sub-perceptual" is the operative word: at a real microdose, you don't feel high, you don't hallucinate, you don't have a "trip." The dose is small enough that, ideally, you can keep working, parenting, driving, and doing the rest of your daily life.
The most common protocols are:
- The Fadiman protocol — one dose day, two off-days, for several weeks. Named for psychologist James Fadiman, who documented it in The Psychedelic Explorer's Guide.
- The Stamets stack — psilocybin combined with lion's mane mushroom and niacin, on a four-days-on, three-days-off schedule. Popularized by mycologist Paul Stamets.
- Every-other-day dosing — simpler schedule, often used informally.
None of these protocols have been validated in randomized clinical trials for PTSD. They exist as conventions, not as treatments.
Microdosing sits in a separate category from psychedelic-assisted therapy, which uses a single, much larger dose alongside structured psychotherapy. The two are studied separately, and findings from one don't automatically transfer to the other.
What controlled studies have actually found
A 2024 review in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging identified 14 controlled studies of microdosing — all of them using LSD, all of them in healthy adults, none of them in clinical populations like veterans with PTSD (Murphy et al., 2024).
The headline findings from those 14 studies, paraphrased:
- Low doses of LSD (5–20 micrograms) produced acute changes in blood pressure, sleep, brain connectivity, time perception, and mood.
- Doses of 5 micrograms were generally not perceptible; doses of 10–20 micrograms sometimes were.
- No serious adverse events were reported across any of the controlled studies.
- Repeated dosing (versus single dosing) did not produce measurable mood or cognition improvements on standardized scales.
Plainly: the controlled-trial evidence supports microdosing as safe in healthy adults but does not yet show it produces sustained mental-health improvements when given on a microdose schedule. Whether it produces such improvements in people who actually have PTSD, depression, or other conditions remains an open empirical question.
The 2022 systematic review by Polito & Liknaitzky in Neuroscience & Biobehavioral Reviews reached a similar bottom line: substantial public enthusiasm, real subjective reports of benefit, sparse clinical evidence so far (Polito & Liknaitzky, 2022).
Is it the LSD, or is it the expectation?
This is the question the field has been wrestling with for several years. Self-report studies — large surveys of people who already microdose — consistently find that microdosers report better mood, less anxiety, less depression than non-microdosers (Rootman et al., 2021). That's a real signal, but it's not strong evidence the drug is doing the work, because microdosers and non-microdosers differ in many ways beyond the dose.
The most ambitious attempt to control for that was Szigeti et al. (2021), an unusual study published in eLife. Participants prepared their own capsules — some with microdoses, some empty placebos — sealed them in numbered envelopes, and then took them blind to which was which. Across the cohort, self-reported benefits were nearly identical between the microdose arm and the placebo arm (Szigeti et al., 2021).
A 2024 rapid review by Polito and Liknaitzky in the Journal of Psychopharmacology went further, surveying the entire controlled-study literature on low-dose LSD and psilocybin. Their conclusion: "the totality of available evidence does not support the claim that microdoses produce reliable benefits beyond placebo" (Polito & Liknaitzky, 2024).
Two things can be true at once. Placebo effects are real changes in real people — pain relief, mood lift, behavior change. Calling something a placebo effect is not the same as calling it imaginary. But if a clinical claim depends on the active ingredient doing the work (and not the ritual, the expectation, the schedule, the community around it), the active-ingredient claim is not yet supported for microdosing.
Where the evidence stands: a lot of veterans report meaningful benefit from microdosing. The research has not yet established whether the benefit comes from the molecule, the practice, or some combination. That's an open question, not a settled one in either direction.
What does that mean for combat PTSD?
As of mid-2026, no peer-reviewed study has examined microdosing in U.S. combat veterans with PTSD. None. The literature is silent on this specific population doing this specific practice.
The closest adjacent evidence comes from full-dose psychedelic trials that included veterans:
- MDMA-assisted therapy has the deepest evidence base in PTSD generally — the Mitchell et al. (2021, 2023) Phase 3 trials in Nature Medicine showed meaningful symptom reduction in mixed populations including veterans.
- Single-dose psilocybin for veterans with severe treatment-resistant depression — Ellis et al. (2024) reported 60% response and 53% remission at three weeks in 15 veterans, with co-occurring PTSD in many participants not significantly affecting outcomes.
- Ibogaine and 5-MeO-DMT in Special Operations Forces veterans with combined PTSD and traumatic brain injury — Davis et al. (2020, 2023) and Cherian et al. (2024) (see full bibliography on /veterans-psychedelics).
All of these used full perceptual doses in clinical settings. None of them are microdose studies. Their findings inform but do not answer the question of whether microdosing — done by a veteran, in daily life, outside clinical structure — does anything similar.
That's the gap. And it's not a small one.
Why the Microdosing Vets study exists
Clinical trials answer one specific question: does this intervention, on average, under controlled conditions, produce measurable change on standardized outcomes? That's important, but it's not the only question worth asking.
Qualitative research answers a different question: what is this experience actually like, and what does it do in the daily life of the person doing it? The methods are interviews, careful coding of language, attention to what participants themselves notice — not standardized scales filled out in a research clinic.
For microdosing in combat veterans, the qualitative question is the more pressing one right now, because:
- Many veterans are already microdosing, outside any research setting, and that knowledge is being lost.
- What veterans notice changing — sleep, irritability, hypervigilance, relationship friction, intrusive memory patterns — is not the same as what standardized PTSD scales measure.
- How microdosing fits into (or doesn't fit into) the rest of a veteran's recovery — therapy, medication, exercise, community, work — is exactly the kind of context a clinical trial filters out by design.
- Future randomized trials will be better designed if they're informed by the lived experience of the population they're meant to study.
That's the gap the Microdosing Vets study is addressing — an ethics-approved doctoral research project at the California Institute of Integral Studies (CIIS) doing qualitative interviews with U.S. combat veterans who have microdosed LSD for PTSD-related reasons. Results have not yet been published; the study is currently recruiting.
What you should know — informationally
This section is information, not advice. The Microdosing Vets program does not recommend microdosing to anyone. The legal and clinical landscape varies by state, by service status, and by individual circumstance.
Legal context
LSD and psilocybin are both Schedule I substances under U.S. federal law. Possession and use are federally illegal regardless of dose. Some states (Oregon, Colorado, with limited municipal frameworks elsewhere) have created local exceptions for psilocybin in specific clinical contexts; none of those state frameworks cover microdosing in daily life. Active-duty service members are also bound by Department of Defense substance-use policy regardless of state law.
VA benefits and security clearance
Disclosing illegal substance use to the U.S. Department of Veterans Affairs (VA) or to a clearance-granting authority is a personal decision with potentially serious consequences. The Microdosing Vets study does not share participant data with the VA, with any clearance-granting authority, or with law enforcement — that's part of the ethics-approval design. But that protection covers study participation, not your underlying use. Talk to a veterans-affairs attorney or your security officer if you have questions about your specific situation.
Safety considerations
The controlled-study evidence base reports no serious adverse events from microdosed LSD in healthy adults (Murphy et al., 2024). That is not a guarantee of safety in any specific person — particularly anyone with personal or family history of psychotic disorders, anyone on medications that affect serotonin (SSRIs, SNRIs, lithium, MAOIs), or anyone with a heart condition. None of those interactions have been formally studied in the microdose context. Free, ongoing mental health care for veterans exists; it's worth knowing about before considering any other approach.
Substance sourcing
The Microdosing Vets program takes no position on, and offers no help with, sourcing substances. Veterans who microdose are doing so through routes outside any clinical framework, and the dose, purity, and identity of substances sourced informally cannot be guaranteed. This is one of the real risks the qualitative research is documenting.
Frequently asked
Short answers to questions that come up most often. Each links back to relevant sections above where appropriate.
Does microdosing help with PTSD?
Nobody knows yet. There are no published randomized controlled trials on microdosing for post-traumatic stress disorder (PTSD) specifically. The clinical evidence base on microdosing in general — at any dose, for any condition — is still small and mostly drawn from healthy adult laboratory studies, where the strongest finding is that low doses of LSD are safe rather than that they treat anything. Veterans who report relief from microdosing are sharing real subjective experiences that science has not yet caught up to.
What's the difference between microdosing and psychedelic-assisted therapy for PTSD?
Psychedelic-assisted therapy uses a full perceptual-altering dose alongside structured psychotherapy sessions — that's what the MDMA, psilocybin, and ibogaine trials for veterans study. Microdosing uses sub-perceptual doses (roughly one-tenth of a full dose) on a recurring schedule, typically without therapy sessions and often outside any clinical structure. The two have completely separate evidence bases, and findings do not transfer between them.
What's the Fadiman protocol?
Named for psychologist James Fadiman, who described it in The Psychedelic Explorer's Guide (2011). The protocol is one dose day, two off-days, repeated for several weeks. It's by far the most common microdosing schedule in the wild, but it has not been validated in any randomized trial for PTSD or any other condition. Other protocols (the Stamets stack, the every-other-day schedule) exist but have similar gaps in formal study.
Is the placebo effect explaining microdosing benefits?
The most rigorous attempt to answer this question is Szigeti et al. (2021), a self-blinding citizen-science study in eLife. It found that participants' self-reported benefits from microdosing did not significantly exceed placebo. A rapid review by Polito and Liknaitzky (2024) reached a similar conclusion across the existing controlled-study evidence. That doesn't mean microdosers aren't experiencing real changes — placebo effects are real changes. It does mean the active-ingredient explanation is not yet supported by controlled evidence.
Are there any published studies on microdosing for veterans specifically?
Not yet. As of mid-2026, no peer-reviewed study has examined microdosing in U.S. combat veterans. There are full-dose psilocybin studies that included veterans — Ellis et al. (2024) on treatment-resistant depression is the most recent — but those use a single 25 mg dose, not a microdose. The Microdosing Vets dissertation study at the California Institute of Integral Studies (CIIS) is the first ethics-approved qualitative study of combat veterans who have microdosed LSD. Results have not yet been published.
Is microdosing legal for veterans in the United States?
LSD and psilocybin are both Schedule I substances under U.S. federal law, which means possession and use are federally illegal regardless of dose. Some states (Oregon, Colorado, with limited municipal frameworks elsewhere) have created local exceptions for psilocybin in specific clinical contexts. None of those state frameworks apply to microdosing in daily life. Active-duty service members are also subject to Department of Defense substance-use policy regardless of state law.
Will microdosing affect VA benefits or a security clearance?
Disclosing illegal substance use to the VA or to a clearance-granting authority is a personal decision with potentially serious consequences. The Microdosing Vets study does not share participant data with the U.S. Department of Veterans Affairs (VA), with any clearance-granting authority, or with law enforcement — that's part of the ethics-approval design. But this page is not the place to make decisions about disclosure. Talk to a veterans-affairs attorney or your security officer if you have questions about your specific situation.
Why study this qualitatively instead of running a clinical trial?
Clinical trials answer the question "does this work, on average, under controlled conditions?" Qualitative research answers a different question: "what is this actually like, and what does it do in the daily life of the person doing it?" Both are valuable. The Microdosing Vets study is qualitative because the gap in the literature is qualitative — clinical trials are happening elsewhere, but nobody is rigorously documenting the lived experience of combat veterans who already microdose. The two streams of research inform each other.
Sources cited on this page
For the full peer-reviewed bibliography on veterans and psychedelics, see Veterans and Psychedelics: the research.
Cited in order of appearance
- Murphy, R. J., Muthukumaraswamy, S., & de Wit, H. (2024). Microdosing psychedelics: Current evidence from controlled studies. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 9(5), 500–511. https://doi.org/10.1016/j.bpsc.2024.01.002
- Polito, V., & Liknaitzky, P. (2022). The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neuroscience & Biobehavioral Reviews, 139, 104706. https://doi.org/10.1016/j.neubiorev.2022.104706
- Rootman, J. M., Kryskow, P., Harvey, K., Stamets, P., Santos-Brault, E., Kuypers, K. P. C., Polito, V., Bourzat, F., & Walsh, Z. (2021). Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports, 11(1), 22479. https://doi.org/10.1038/s41598-021-01811-4
- Szigeti, B., Kartner, L., Blemings, A., Rosas, F., Feilding, A., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife, 10, e62878. https://doi.org/10.7554/eLife.62878
- Polito, V., & Liknaitzky, P. (2024). Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. Journal of Psychopharmacology, 38(8), 701–711. https://doi.org/10.1177/02698811241254831
- Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
- Mitchell, J. M., Ot'alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., & Yazar-Klosinski, B. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473–2480. https://doi.org/10.1038/s41591-023-02565-4
- Ellis, S., Bostian, C., Feng, W., Fischer, E., Schwartz, G., Eisen, K., Lean, M., Conlan, E., Ostacher, M., Aaronson, S. T., & Suppes, T. (2024). Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression — A first-in-kind open-label pilot study. Journal of Affective Disorders, 369, 381–389. https://doi.org/10.1016/j.jad.2024.04.105
If you've microdosed for PTSD, your experience belongs in the record.
The Microdosing Vets study is the first qualitative research project documenting how combat veterans actually use microdosing in daily life. Five-minute eligibility screening, run by a fellow combat veteran.
Take the 5-Min Screening → Back to Resources